Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial
Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial
复制标题
DOI：
10.1111/j.1600-0412.2012.01350.x
复制
发表时间：
2012-04-01
影响因子：
4.3
通讯作者：
Mosbah, Alaa A.
中科院分区：
文献类型：
--
作者：
Badawy, Ahmed M.;Elnashar, Aboubakr M.;Mosbah, Alaa A.
目标。比较芳香化酶抑制剂与促性腺激素释放激素激动剂治疗绝经前妇女子宫血栓的疗效。设计。一项前瞻性随机对照研究。设置。一个大学医院和一个私人诊所。人口。子宫血栓32例。方法。患者随机分配接受口服来曲唑（2.5mg/天）或皮下促性腺激素释放激素激动剂（戈舍瑞林，3.6mg） 12周。子宫和腺肌瘤体积在基线和治疗期间的4周，8周和12周进行测定。结果的措施。在基线和治疗4周、8周、8周和12周时进行测量，并计算平均值。评估开始时和12周后的症状。结果。两组治疗后子宫总体积差异无统计学意义（4周、8周、12周时分别为20.1、15.4、13.0cm3和21.7、15.1、11.7cm3）。治疗4周、8周和12周后，A组和B组的总腺肌瘤体积分别减少了8.6、29.7%和40.9%，而对照组分别减少了5.7、34.6和49.1%。A组2例患者在治疗期间怀孕。结论。芳香酶抑制剂在减少腺肌瘤体积和改善症状方面与促性腺激素释放激素激动剂一样有效。
Objective. To compare the efficacy of aromatase inhibitor vs. gonadotrophin-releasing hormone agonists in treating premenopausal women with uterine adenomyosis. Design. A prospective randomized controlled study. Setting. A university hospital and a private practice setting. Population. Thirty-two patients with uterine adenomyosis. Methods. Patients were randomly allocated to receive oral letrozole (2.5mg/day) or a subcutaneous gonadotropin-releasing hormone agonist (goserelin, 3.6mg) for 12 weeks. Uterine and adenomyoma volumes were determined at baseline and during treatment at four, eight and 12 weeks. Outcome measures. Measurements were performed at baseline and during treatment at four, eight 8 and 12 weeks, and mean values were calculated. Symptoms at the start and after 12 weeks were evaluated. Results. No significant differences in the total uterine size between the post treatment uterine volumes in the two groups (20.1, 15.4 and 13.0cm3 vs. 21.7, 15.1 and 11.7cm3, at four, eight and 12 weeks, respectively). Total adenomyoma volume decreased by 8.6, 29.7 and 40.9% vs. 5.7, 34.6 and 49.1% after four, eight and 12 weeks of treatment, in group A and B, respectively. Two patients became pregnant in group A during treatment. Conclusions. Aromatase inhibitors are as effective as gonadotropin-releasing hormone agonists in reducing adenomyoma volume and improving symptoms.